Blog

With $69M Deal, AbbVie Turns to Voyager for an Alzheimer’s Gene Therapy – Xconomy


Xconomy

With $69M Deal, AbbVie Turns to Voyager for an Alzheimer's Gene Therapy
Xconomy
At a time when uncertainty again swirls around the development of Alzheimer's disease drugs, research continues in new ways. Through an alliance this morning, Voyager Therapeutics will team with AbbVie to try to use gene therapy tools to help attack
AbbVie steers past the wreckage, reserves $224M to kick off once-and-done gene therapy with Voyager to fight …Endpoints News


AbbVie and Voyager Therapeutics Announce Global Strategic Collaboration to Develop Potential New Treatments for …Markets Insider
AbbVie doubles down on tau with Voyager Alzheimer's dealFierceBiotech
Seeking Alpha
all 6 news articles »

2018-02-20 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.